Genomic tug of war could boost cancer therapy

By Science X staff

Some patients with myelodysplastic syndromes, like acute myeloid leukemia, benefit from a chemotherapy drug called decitabine that stunts cancer growth. But many others are resistant to decatibine's effects or become resistant over time. Wilmot Cancer Institute

You are viewing a robot-friendly page.Click hereto reload in standard format.